

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APRIL 24, 1997

PTAS



\*100365306A\*

AMGEN  
DANIEL R. CURY  
U.S. PATENT OPERATIONS/DRC, DEPT. 431  
1840 DEHAVILLAND DRIVE  
THOUSAND OAKS, CALIFORNIA 91320-1789

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/24/1997

REEL/FRAME: 8371/0136  
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:  
SYNERGEN, INC.

DOC DATE: 12/31/1994

ASSIGNEE:  
AMGEN INC.  
1840 DEHAVILLAND DRIVE  
THOUSAND OAKS, CALIFORNIA  
91320-1789

SERIAL NUMBER: 08453176 50-225 US K  
PATENT NUMBER:

FILING DATE: 05/30/1995  
ISSUE DATE:

SERIAL NUMBER: 08452242 50 225 US J  
PATENT NUMBER:

FILING DATE: 05/26/1995  
ISSUE DATE:

SERIAL NUMBER: 08452229 50 225 US I  
PATENT NUMBER:

FILING DATE: 05/26/1995  
ISSUE DATE:

SERIAL NUMBER: 08451374 50 225 US H  
PATENT NUMBER:

FILING DATE: 05/26/1995  
ISSUE DATE:

SERIAL NUMBER: 08453183	SO-225 US G	FILING DATE: 05/30/1995
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 08448245	SO-225 US F	FILING DATE: 05/23/1995
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 08182183	SO-225 US E	FILING DATE: 05/23/1994
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 08052541	SO-225 US D	FILING DATE: 04/20/1993
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 07855413	SO-225 US C	FILING DATE: 03/19/1992
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 07788423	SO-225 US B	FILING DATE: 11/06/1991
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 07774109	SO-225 US A	FILING DATE: 10/08/1991
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 07764685	SO-225 US O	FILING DATE: 09/20/1991
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 08446383	SO-325 US A	FILING DATE: 05/22/1995
PATENT NUMBER:		ISSUE DATE:
SERIAL NUMBER: 08340821	SO-325 US O	FILING DATE: 11/15/1994
PATENT NUMBER:		ISSUE DATE:

DOROTHY RILEY, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

03-04-1997

FEB 24 1997

Revised Form PTO-1595  
(Rev. 6-93)U.S. Department of Commerce  
Patent and Trademark Office

M20 22497

100365306

To the Honorable Commissioner of

and original documents or copy thereof.

1. Name of conveying party:  
Synergen, Inc.Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Amgen Inc.

Internal

Address:

3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other

Street

Address:

1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

Execution Date: December 31, 1994

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application numbers:

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application Nos.: 08/453,176; 08/452,242;  
08/452,229; 08/451,374; 08/453,183; 08/448,245;  
08/182,183; 08/052,541; 07/855,413; 07/788,423  
07/774,109; 07/764,685; 08/446,383; 08/340,821

B. Patent Nos.

Additional numbers attached? ☐ Yes ☒ No5. Name and address of party to whom correspondence  
concerning document should be mailed:

Name: U.S. Patent Operations/DRC

Internal Address: Dept. 431

Amgen

Street Address: 1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

6. Total number of applications and patents involved: 14

7. Total fee (37 CFR 3.41).....\$ 560.00

☐ Enclosed☒ Authorized to be charged to deposit account.

8. Deposit account number: 01-0519

☒ The Commissioner is hereby authorized to charge any  
additional filing fees which may be required or credit  
any overpayment to Deposit Account No. 01-0519

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of  
the original document

Daniel R. Curry

Name of Person Signing

Signature

February 18, 1997

Date

Total number of pages including cover sheet, attachments, and document: 5

410 US 01-0519 03/03/97 08453176

41-82 381

560.0000

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Box  
Assignment, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

2/18/97

Date

Freddie Craft  
Signature

## EXHIBIT A

### U.S. Patent Application

<u>Serial No:</u>	<u>Date Filed</u>	<u>Title</u>
08/453,176	05-30-95	Glial Cell Line-Derived Neurotrophic Factor ("GDNF")
08/452,242	05-26-95	Same
08/452,229	05-26-95	Same
08/451,374	05-26-95	Same
08/453,183	05-30-95	Same
08/448,245	05-23-95	Same
08/182,183	05-23-95	Same
08/052,541	04-20-93	Same
07/855,413	03-19-92	Same
07/788,423	11-06-91	Same
07/774,109	10-08-91	Same
07/764,685	09-20-91	Same
08/446,383	05-22-95	Method for Using GDNF as a Neuroprotective Agent
08/340,821	11-15-94	Same

### Foreign Patent Application

<u>Serial No/Country:</u>	<u>Date Filed</u>	<u>Title</u>
26811/92/AU	09-17-92	Glial Derived Neurotrophic Factor
1053/BS	09-17-92	Same
2119463/CA	09-17-92	Same
92921022.7/EP	09-17-92	Same
941285/FI	09-17-92	Same
P9400717/HU	09-17-92	Same
103223/IE	09-17-92	Same
103223/IL	09-17-92	Same
506234/93/JP	09-17-92	Same
700860/94/KR	09-17-92	Same
925293/MX	09-17-92	Same
9409222/NO	09-17-92	Same
244392/NZ	09-17-92	Same
44956/PH	09-18-92	Same
100879/PT	09-17-92	Same
81108487/TW	09-17-92	Same
US92/07888/PCT	09-17-92	Same
92/7159/ZA	09-17-92	Same
115996/IL	11/12/95	Methods of Using GDNF as a Neuroprotective Agent
IB95/01004/PCT	11/13/95	Same
95/9714/ZA	11/15/95	Same

## **ASSIGNMENT OF PATENT RIGHTS**

This Assignment of Patent Rights (hereafter, "Assignment") is made as of December 31, 1994 by Synergen, Inc., a Delaware corporation, having its principal place of business at c/o Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Synergen") to Amgen Inc., a Delaware corporation, having its principal place of business at Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Amgen").

### **RECITALS**

1. Synergen is the exclusive owner of all right, title to, and interest in patent applications relating to Glial Cell Line-Derived Neurotrophic Factor pending in the United States Patent and Trademark Office and all foreign counterparts (referred to jointly hereafter as the "Patent Applications"), including those set forth on attached Exhibit A.
2. Synergen has agreed that the Patent Applications are unencumbered and that Synergen has full right and lawful authority to assign and convey the same in the manner set forth herein.
3. Synergen has agreed to transfer and assign all of its right, title to, and interest in the Patent Applications to Amgen.

### **AGREEMENT**

In consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, Synergen hereby sells, transfers and assigns to Amgen, its successors and assigns the entire right, title and interest in, to and under the Patent Applications, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and Patents and of all other countries which may be granted for such inventions, or any of them including divisional, continuation, continuation-in-part, renewal or substitute applications based on the above-identified Patent Applications, any reissue or re-examination of patents and Letters Patent, all such inventions and all rights in such

Patents and Letters Patent to be held and enjoyed by Amgen for its own use and enjoyment to the full end of the term or terms for which such Patents and Letters Patent may be granted.

Synergen further transfers and assigns all claims for damages and/or injunctive relief by reason of past infringement of the Patent Applications and all foreign counterparts thereto, with the right to sue for and collect the same for Amgen's own account and use.

Synergen further transfers and assigns to Amgen the full exclusive benefits of, and all rights, privileges and advantages appertaining to the Patent Applications.

IN WITNESS WHEREOF, the duly authorized representative of Synergen has executed this Assignment as of the date first written above.

Synergen, Inc.

By: 

Name: Robert Amyeh

Title: Senior Vice President,  
Finance & Corporate Development

## APOSTILLE

*(Convention de La Haye du 5 octobre 1961)*


1. Country: United States of America  
This public document
2. has been  
signed by C. MICHI HASEGAWA
3. acting in the capacity of Notary Public, State of California
4. bears the seal/stamp of C. MICHI HASEGAWA Notary Public,  
State of California

## CERTIFIED

5. at Sacramento, California
6. the 2ND DAY OF MAY 1996
7. by Deputy Secretary of State, State of California
8. No NP02619
9. Seal/Stamp
10. Signature:

SOS/NP 28 12/95


*C. Michi Hasegawa*

The seal is circular with the text "OFFICE OF THE SECRETARY OF STATE" around the perimeter. Inside the circle is a smaller seal featuring the state seal of California, which includes a grizzly bear and the word "EUREKA".

# CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California  
County of Ventura  
On April 23, 1996 before me, C. Michi Hasegawa  
Date Name and Title of Officer (e.g., "Jane Doe, Notary Public")  
personally appeared Robert S. Att'yeh  
Name(s) of Signer(s)

☒ personally known to me - OR - ☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



WITNESS my hand and official seal.

C. Michi Hasegawa  
Signature of Notary Public

## OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

### Description of Attached Document

Title or Type of Document: Assignment of Patent Rights - Synergen  
Document Date: December 31, 1994 Number of Pages: 3

Signer(s) Other Than Named Above: \_\_\_\_\_

### Capacity(ies) Claimed by Signer(s)

Signer's Name: \_\_\_\_\_

- ☐ Individual  
☒ Corporate Officer  
Title(s): SVP - Finance & Corp Dev  
☐ Partner — ☐ Limited ☐ General  
☐ Attorney-in-Fact  
☐ Trustee  
☐ Guardian or Conservator  
☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

RIGHT THUMBPRINT  
OF SIGNER  
Top of thumb here

Signer's Name: \_\_\_\_\_

- ☐ Individual  
☐ Corporate Officer  
Title(s): \_\_\_\_\_  
☐ Partner — ☐ Limited ☐ General  
☐ Attorney-in-Fact  
☐ Trustee  
☐ Guardian or Conservator  
☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

RIGHT THUMBPRINT  
OF SIGNER  
Top of thumb here